Supernus Pharmaceuticals (SUPN) Stock Statistics & Valuation Metrics

Supernus Pharmaceuticals has a market cap or net worth of $2.91B. The enterprise value is $2.82B.

Supernus Pharmaceuticals has 57,581,710 shares outstanding. The number of shares has decreased by -2.65% in one year.

Supernus Pharmaceuticals’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -2.58%.

The current PE Ratio of Supernus Pharmaceuticals is ―. Supernus Pharmaceuticals’s PEG ratio is 0.48.

In the last 12 months, Supernus Pharmaceuticals had revenue of 718.95M and earned -38.55M in profits. Earnings per share was -0.68.

In the last 12 months, operating cash flow was 47.33M and capital expenditures -1.34M, giving a free cash flow of 45.99M billion.

Supernus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Supernus Pharmaceuticals upcoming earnings date is May 12, 2026, After Close (Confirmed).

Supernus Pharmaceuticals as a current ratio of 1.90, with Debt / Equity ratio of 3.86%

In the past 12 months, Supernus Pharmaceuticals has paid -10.48M in taxes.

Supernus Pharmaceuticals EV to EBITDA ratio is 66.29, with an EV/FCF ratio of 59.10.

Supernus Pharmaceuticals has $308.67M in cash and marketable securities with $40.98M in debt, giving a net cash position of $267.69M billion.

Gross margin is 85.54%, with operating margin of -5.13%, and net profit margin of -5.36%.

The average price target for Supernus Pharmaceuticals is $63.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy